Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
Validation of the Odesa Criteria 2026 (OC26) for the Diagnosis of Autoimmune Pancreatitis
Military Medical Clinical Center of the Southern Region, Ukraine
82 participants
May 1, 2026
OBSERVATIONAL
Conditions
Summary
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis. The study evaluates diagnostic accuracy and reproducibility of OC26 across clinical, serological, morphological, and histological domains.
Eligibility
Inclusion Criteria3
- Adults (≥18 years) undergoing evaluation for suspected autoimmune pancreatitis.
- Availability of clinical, serological, imaging, and/or histological data required for OC26 scoring.
- Ability to provide informed consent (for prospective participants).
Exclusion Criteria3
- Confirmed alternative diagnosis explaining pancreatic findings (e.g., pancreatic cancer, acute pancreatitis of other etiology).
- Incomplete diagnostic data preventing OC26 scoring.
- Prior pancreatic surgery altering diagnostic interpretation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants receive no assigned intervention. Diagnostic evaluation follows routine clinical practice.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07536841